Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
AN

NASDAQ · ANGO

AngioDynamics, Inc.

Healthcare · Medical - Instruments & Supplies

$11.99

Down-$0.36 (-2.91%)

Updated Nov 1, 2026, 8:04 PM

SID Score

3.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
471.53M
P/E ratio
-17.09
Dividend yield
0.00%
52-week range
$9.39 – $16.29
Volume
475.83K
Avg. volume
570.39K

Price performance · ANGO

ANGO price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

ANGO closed at $11.99 after 20 trading sessions, down 22.84% for the selected period.

Last close
$11.99
Period change
-22.84%
Period low
$10.90
Period high
$15.54
Daily close
View OHLC price history
ANGO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$12.32$12.34$11.89$11.99475.83K
Oct 29, 2026$12.285$12.43$12.065$12.35476.19K
Oct 28, 2026$12.01$12.37$12.01$12.13570.95K
Oct 27, 2026$12.26$12.4699$12.07$12.26570.6K
Oct 26, 2026$12.32$12.39$12.145$12.17458.83K
Oct 23, 2026$11.93$12.472$11.76$12.365631.33K
Oct 22, 2026$11.85$12.08$11.665$12.02673.15K
Oct 21, 2026$11.81$12.2156$11.66$11.89725.28K
Oct 20, 2026$11.46$11.96$11.46$11.811.37M
Oct 19, 2026$11.29$11.555$11.09$11.39875.92K
Oct 16, 2026$11.61$11.73$11.05$11.24890.7K
Oct 15, 2026$11.05$11.625$11.05$11.581.14M
Oct 14, 2026$10.79$11.48$10.73$11.051.59M
Oct 13, 2026$11.43$11.52$10.62$10.901.35M
Oct 12, 2026$11.42$11.705$11.30$11.401.08M
Oct 9, 2026$11.12$11.97$10.86$11.522.16M
Oct 8, 2026$13.22$13.80$11.06$11.233.07M
Oct 7, 2026$14.20$14.51$14.13$14.191.01M
Oct 6, 2026$15.61$15.655$14.23$14.42847.58K
Oct 5, 2026$15.02$15.63$14.92$15.54636.17K

Latest ANGO news

The latest Smart Investors Daily articles mentioning ANGO.

Stock researchCompany · Overview

ANGO research

Overview

Company profile and research snapshot.

Company profile

AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$18.00
Implied upside
—
Analysts
—
ANGO recent ratings
DateFirmRatingTarget
Oct 13, 2026HC Wainwright & Co.Buy—
Oct 9, 2026Canaccord GenuityBuy—
Jul 15, 2026HC Wainwright & Co.Buy—
Jul 15, 2026Canaccord GenuityBuy—
Apr 6, 2026Freedom BrokerBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 21, 2026

AngioDynamics Announces Publication of DIRECT Study Results and New Category I CPT Code for Pancreatic IRE

LATHAM, N.Y., October 21, 2026--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced two milestones for irreversible electroporation (IRE), the non-thermal ablation technology delivered by the NanoKnife System. The first is the publication of results from the DIRECT study in The Oncologist, in

Yahoo · Oct 14, 2026

AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife® IRE for Prostate and Liver Cancer

LATHAM, N.Y., October 14, 2026--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Humana has updated its Medicare Advantage coverage policy to apply Local Coverage Determination (LCD) L40205 medical necessity criteria for irreversible electroporation (IRE), the non-thermal ablation tec

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By